Church of PeptidesSearch
Portrait of AOD-9604
Pilgrims · 1990s–2000s

AOD-9604

The Fragment with a Measuring Tape

Australia

AOD-9604 is a modified growth-hormone fragment developed as a potential obesity treatment. It was intended to separate fat-related activity from other growth-hormone effects, but that design goal did not establish clinically meaningful weight loss.

Evidence ladder: Controlled human evidenceEducational record
ClassificationPilgrims
Evidence summaryControlled human trials · larger obesity trial negative
OriginAustralia
Scientific record

What the evidence says

Established role or proposed benefit

  • Investigated as a modified growth-hormone fragment for obesity.
  • Designed to explore fat-metabolism effects without full GH activity.

Side effects, risks, and limits

  • No FDA-approved obesity indication.
  • Clinical development did not establish the broad claims now made online.
Doctide’s verdict

The fragment reached human testing, and the weight-loss promise did not hold up in the larger trial. Doctide gives that result more weight than the appealing idea of separating fat loss from growth-hormone effects.

Documented history

Where the real story begins

Metabolic Pharmaceuticals developed AOD-9604 in Australia and advanced it into human obesity trials. FDA’s review records that development for obesity was stopped in 2007 after the larger phase IIb study failed to demonstrate a significant weight-loss advantage over placebo. Historical source.

Australia · 1990s–2000s
Book of the Canon · comic scripture

The laboratory legend

AOD-9604 arrived holding one fragment of growth hormone and a measuring tape. The scale moved in early stories, but the approval stamp never did.

This bold passage is invented comedy, not scientific or historical fact.
Editorial recordProfile editorial revision: October 4, 2026Prepared under the Church of Peptides evidence standardEditorial review: Church of PeptidesIndependent clinical review: none to dateContent evidence reviewed: September 12, 2026
Evidence ledger

Sources

Source links checked: October 4, 2026. This dated advisory-committee briefing assesses evidence and safety concerns; it is not a drug approval or a current compounding authorization.

  1. FDA briefing on AOD-9604, December 2024

Fiction disclosure: The bold laboratory legend is invented. The historical and scientific sections are factual summaries; no invented connective events were added.

Educational entertainment only. Not medical advice, diagnosis, dosing guidance, or a recommendation to obtain or use a product.